Pentec Health Acquires ZOIA Pharma

PAI Partners to acquire Nuzoa from Abac Capital

March 24, 2025

Veterinary

PAI Partners, via its PAI Mid-Market Fund, has agreed to acquire Nuzoa, the leading integrated animal health products and services distributor in Iberia, from Abac Capital. PAI plans to accelerate Nuzoa's growth through further consolidation in the fragmented Iberian market, expansion into other European markets and by developing additional vet-focused services such as digital solutions and laboratory diagnostics.

Olympus Partners Acquires PAI Pharma

February 24, 2025

Pharmaceuticals

Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.

Novo Integrated Sciences / Novo Healthnet Acquire Acenzia Inc.

June 29, 2021

Pharmaceuticals

Novo Integrated Sciences, through its wholly owned subsidiary Novo Healthnet Limited, completed the acquisition of Acenzia Inc., a Windsor, Ontario-based nutraceutical manufacturer and diagnostics developer. The all-share transaction closed on June 24, 2021 and is valued at $14,884,039; Novo said the purchase will give it direct control of development, manufacturing and distribution of wellness products and personalized diagnostics.

CertiPath and ZEVA Acquire SAFE-BioPharma

May 31, 2019

Cybersecurity

CertiPath and ZEVA jointly acquired SAFE-BioPharma, a provider of high-assurance digital identity and cryptography standards for the pharmaceutical, biotechnology, and healthcare industries. The buyers intend to refresh and expand SAFE-BioPharma's policies, specifications, and services to strengthen digital identity trust across regulated health and life-science organizations.

PTC Therapeutics to Acquire Censa Pharmaceuticals

May 6, 2020

Biotechnology

PTC Therapeutics has entered into an agreement to acquire Censa Pharmaceuticals to obtain CNSA-001 (sepiapterin), a Phase 3–ready oral therapy for phenylketonuria (PKU) and other BH4-pathway disorders. Under the deal PTC will pay approximately $10 million cash upfront and up to 850,000 shares of PTC common stock, plus potential development, regulatory and sales milestones totaling hundreds of millions of dollars.

Pfizer's Hospital Business Acquires Arixa Pharmaceuticals

October 22, 2020

Pharmaceuticals

Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.